Mr. Sebastien Plouffe reports

DEFENCE THERAPEUTICS APPOINTS DR. MARK LAMBERMON AS HEAD OF QUALITY AND OPERATIONS

Defence Therapeutics Inc. has appointed Dr. Mark Lambermon, PhD, as head of quality and operations. Dr. Lambermon brings over 20 years of experience spanning pharmaceutical R&D (research and development), biotech innovation, and commercial manufacturing, with a proven record in building and leading quality organizations across the full drug development life cycle.

Dr. Lambermon held roles at AbbVie Inc., and Baxter Healthcare in Chicago, Ill., where he led global CMC (chemistry, manufacturing and controls) programs and supplier and CDMO (contract development and manufacturing organization) qualification/oversight and implemented GMP-compliant (good manufacturing practice) quality systems. Earlier in his career, Dr. Lambermon supervised quality control operations supporting FDA-regulated (U.S. Food and Drug Administration) manufacturing at NantPharma and Monosol Inc. and contributed to the development of AAV-based (adeno-associated virus) gene therapies at Arthrogen BV in Amsterdam, the Netherlands.

"Mark's extensive expertise in quality, regulatory compliance and operations will be pivotal as we advance towards regulatory readiness," said Sebastien Plouffe, founder and chief executive officer of Defence Therapeutics. "He has broad experience designing fit-for-phase quality systems, overseeing global supply chains and prepare organizations for inspection readiness -- exactly the leadership we need to support our next stage of growth as well as to secure strong partnerships with pharma."

"I'm thrilled to join Defence Therapeutics at this pivotal moment," said Dr. Lambermon. "With Accum, we have a real chance to improve outcomes and quality of life for patients facing aggressive cancers. My priority is to build a scalable, phase-appropriate quality organization so that our scientific innovation is matched by operational excellence, regulatory compliance, and -- above all -- patient safety."

Dr. Lambermon holds a PhD in cellular biology from the University of Basel, Switzerland, and completed postdoctoral fellowships at the University of Toronto and Radboud University in the Netherlands. He earned his BSc and MSc in organic and biochemistry at the University of Nijmegen in the Netherlands.

The company has granted 100,000 incentive stock options to Dr. Lambermon, in accordance with the terms and conditions of Defence's omnibus incentive plan. The options are vested immediately and exercisable at a price of 80 cents per share for a period of three years from the date of grant.

About Defence Therapeutics Inc.

Defence is a publicly traded, clinical-stage biotechnology company developing and engineering the next generation of ADC (antibody-drug conjugate) products using its proprietary platform. The core of Defence Therapeutics' platform is the Accum technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.

We seek Safe Harbor.